Last Update 24 Feb 26

Fair value Decreased 9.57%

QDEL: Long Term Lifotronic Supply Agreement Will Support Future Upside

QuidelOrtho's blended analyst price target has shifted from roughly $38.33 to $34.67 as analysts refresh their models around updated growth, profitability and P/E assumptions following mixed target revisions from several major firms.

Analyst Commentary

Recent research updates on QuidelOrtho point to a mixed but active debate around the stock, with several firms adjusting their price targets in both directions as they revisit growth and profitability assumptions.

Bullish Takeaways

Bullish analysts who raised targets highlight potential for better execution against current forecasts, which they see as not fully reflected in the blended target of about $34.67.
The higher price targets from JPMorgan and Citi suggest some confidence that QuidelOrtho can deliver on its growth plans, which they link to support for a higher valuation multiple over time if execution holds.
Previous upward adjustments from firms that follow the name closely indicate that, even with recent trims elsewhere, there is still a camp that views the current share price as not fully pricing in the company’s longer term earnings power.
Overall, the cluster of raised targets signals that a subset of the Street sees room for upside if QuidelOrtho can meet or beat its operational and profitability goals.

Bearish Takeaways

Bearish analysts, including those who recently lowered targets, are more cautious on how quickly QuidelOrtho can translate its pipeline and portfolio into consistent earnings growth that would justify higher P/E assumptions.
The reduction in at least one major target points to concerns that earlier expectations may have been too optimistic, which feeds into a lower blended target in the mid $30s.
Some on the Street appear wary of execution risk, especially around profitability, and are trimming their numbers to reflect what they view as a more conservative path for margins and cash generation.
The mix of both higher and lower target moves underlines that there is still uncertainty around the timing and reliability of future growth, which can keep a cap on how aggressive some analysts are willing to be with their valuations.

What's in the News

QuidelOrtho entered a long term supply agreement with Lifotronic Technology to expand its global immunoassay portfolio outside the US, gaining access to multiple high throughput and low to mid volume analyzer platforms with a menu of more than 70 assays and over 25 that are not currently available on the VITROS system (Key Developments).
The Lifotronic collaboration is planned to help QuidelOrtho compete for full menu tenders and serve a broader range of labs, from smaller low volume sites to large high throughput settings that require scalable capacity and broad test menus (Key Developments).
QuidelOrtho announced that Chief Financial Officer Joseph M. Busky plans to retire effective June 30, 2026, with the company starting a search for a successor and Busky expected to stay on in an advisory role after his retirement to support the transition (Key Developments).
The company issued earnings guidance for fiscal 2026, expecting total revenues in a range of US$2.7b to US$2.9b (Key Developments).

Valuation Changes

Fair Value: Blended fair value moved from $38.33 to $34.67. This reflects a reduction of about 9.5% in the modeled estimate.
Discount Rate: The discount rate increased from 10.79% to 11.77%, indicating a higher required return in the updated assumptions.
Revenue Growth: The revenue growth assumption shifted from 3.06% to 3.32%, representing a modest change in the projected top line trend.
Net Profit Margin: The net profit margin moved from 12.92% to 13.33%, indicating a small uplift in expected profitability.
Future P/E: The future P/E multiple moved from 9.37x to 8.32x, reflecting a lower valuation multiple applied in the latest model.

7 views

Key Takeaways

Expansion into global and underpenetrated markets, alongside demographic trends, positions QuidelOrtho for sustained diagnostic demand and stable long-term revenue streams.
Operational efficiency, high-value diagnostics innovation, and improved customer satisfaction enhance margins, market share, and resilience against future industry challenges.
Post-pandemic demand decline, product discontinuations, regional pricing pressures, integration challenges, and lagging innovation threaten revenue, margins, and competitive positioning.

Catalysts

About QuidelOrtho

Provides diagnostic testing solutions.What are the underlying business or industry changes driving this perspective?

Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China-where differentiated technology, low market share, and a large runway for immunoassay growth exist-positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance, which should drive topline revenue growth.
Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform addresses the trend toward fast, decentralized testing and is likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.
Demographic shifts, including an aging global population and increasing prevalence of chronic and lifestyle diseases, support baseline volume growth in key QuidelOrtho diagnostic platforms spanning clinical chemistry, immunoassays, and molecular diagnostics, underpinning long-term, stable revenue streams.
Continued operational improvements-such as indirect procurement cost reductions, manufacturing site consolidation, and successful ERP system integration-are yielding significant margin and EBITDA gains, with incremental savings expected to directly benefit net margins and EPS into 2026 and beyond.
Strong and improving customer satisfaction, recognized by top service rankings, and strategic talent acquisition in regulatory affairs are likely to support customer loyalty and regulatory execution, helping defend and expand market share, thus providing resilience and future upside potential to earnings.

QuidelOrtho Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming QuidelOrtho's revenue will grow by 2.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -17.0% today to 0.6% in 3 years time.
Analysts expect earnings to reach $17.2 million (and earnings per share of $0.26) by about September 2028, up from $-466.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $102.5 million in earnings, and the most bearish expecting $-38.0 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 237.3x on those 2028 earnings, up from -4.0x today. This future PE is greater than the current PE for the US Medical Equipment industry at 28.6x.
Analysts expect the number of shares outstanding to grow by 0.96% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 10.75%, as per the Simply Wall St company report.

QuidelOrtho Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Post-pandemic normalization is creating persistent drag on QuidelOrtho's revenues and profit margins, with COVID-related revenue falling sharply (COVID testing revenue down 52% YoY, and 2025 full year COVID guidance reduced by $40 million) and no new expected drivers to offset this high-margin product line; this directly threatens both top-line revenue and net margins.
The winding down and discontinuation of certain product lines-such as the Donor Screening business and the Savanna molecular platform (which triggered $150 million in non-cash charges and eliminates future cash flows from those assets)-highlights risks in portfolio concentration and product obsolescence, ultimately reducing future revenue diversification and potentially impacting future earnings and profitability.
Shifts in healthcare purchasing behavior in key international markets, particularly China, including volume-based procurement (VBP), reimbursement changes, and potential panel unbundling (DRG) processes, pose ongoing risks of price erosion and volume pressure; while the company claims limited near-term impact, further expansion in China may be constrained by these secular and regulatory headwinds, risking long-term revenue and margin growth in that region.
Execution risk from large-scale integrations (such as the ongoing integration of Ortho Clinical and planned acquisition of LEX Diagnostics) could lead to elevated costs, operational disruptions, or delays in achieving anticipated synergies; additional restructuring charges and slow synergy realization may compress margins and negatively impact net earnings.
Intensifying industry competition and rapid shifts toward decentralized, point-of-care, and next-generation diagnostic technologies may outpace QuidelOrtho's current R&D and platform upgrades (evidenced by recent product discontinuations and reliance on yet-to-be-approved new platforms like LEX), increasing the risk of market share loss, revenue declines, and the need for higher R&D spending that weighs on overall profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $43.429 for QuidelOrtho based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $62.0, and the most bearish reporting a price target of just $26.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $3.0 billion, earnings will come to $17.2 million, and it would be trading on a PE ratio of 237.3x, assuming you use a discount rate of 10.8%.
Given the current share price of $27.61, the analyst price target of $43.43 is 36.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on QuidelOrtho?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Global Expansion And Decentralized Testing Will Unlock Future Potential